LAS VEGAS, April 14, 2017 /PRNewswire/ -- The International Society for CNS Drug Development (ISCDD) announced today that Raymond Sanchez, M.D., Senior Vice President, Global Clinical Development at Otsuka Pharmaceutical Development & Commercialization (OPDC), has been elected as the Chairman of the Executive Committee for the ISCDD.
Dr. Sanchez succeeds Dr. George Garibaldi, who has served as Chairman of the ISCDD Executive Committee since 2012. “I am pleased to be succeeded by Dr. Ray Sanchez. His tireless dedication to furthering the development of therapies in CNS makes him an obvious choice for our next Chairman,” said Dr. Garibaldi.
“For the past fifteen years, the ISCDD has played a significant role in shaping the present and future development of CNS therapies,” said Dr. Sanchez. “I am committed to continue to help make strides with others in CNS endeavors and look forward to substantial progress over the next four years as we incorporate and leverage innovative approaches to development.”
The International Society for CNS Drug Development (ISCDD) is a non-profit, independent leadership forum founded in 2002 to improve central nervous system drug development through collaboration amongst stakeholders including industry, academia, and government.
For more information, please contact:
Erica Moore
ISCDD Secretariat
O: 702-992-0784
M: 610-613-3524
154969@email4pr.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/raymond-sanchez-elected-chairman-of-iscdd-executive-committee-at-iscdd-2017-annual-meeting-300439814.html
SOURCE ISCDD
